How to Inject Semaglutide: A Step-by-Step Overview

Learning how to inject semaglutide at home starts with one principle: the medication is designed as a once-weekly subcutaneous injection, and the exact technique belongs to your specific product’s Instructions for Use (IFU) and your prescriber or pharmacist, not to a generic article. According to the FDA-approved labels for Wegovy (semaglutide) and Ozempic (semaglutide), the medicine is injected under the skin of the abdomen, thigh, or upper arm. This overview walks through the general mechanics so the steps feel less unfamiliar. It is not personalized medical advice, and it will not tell you what dose to take.

This is general education, not medical advice. For anything specific to you, contact your prescriber or pharmacist.

Where is semaglutide injected, and how often?

Both FDA-approved semaglutide products are injected subcutaneously (into the fatty layer just under the skin) once weekly. The three label-permitted sites are the abdomen, thigh, or upper arm. The Wegovy label states that “the time of day and the injection site can be changed without the need for a dosage modification” — so you do not need to change anything about your prescribed dose simply because you switch from, say, your abdomen to your thigh one week.

“Rotating sites” is grounded in the Ozempic label, which instructs patients to “use a different injection site each week when injecting in the same body region.” For a deeper look at site selection and rotation, see our companion overview on semaglutide injection sites. Picking a consistent weekly day helps with adherence; the Ozempic label notes the dosing day “can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours).”

What is the difference between a semaglutide pen and a vial?

This distinction is the most important safety point in the entire process. Wegovy and Ozempic, both made by Novo Nordisk, are the FDA-approved semaglutide products, supplied as prefilled pens with a built-in dosing mechanism and reviewed by the FDA for safety, effectiveness, and quality. By contrast, compounded semaglutide is not FDA-approved, and the FDA does not review it for safety, effectiveness, or quality before it is marketed.

The vial-and-syringe presentation carries a documented hazard. In a July 2024 alert, the FDA reported dosing errors — some requiring hospitalization — in which patients gave themselves as much as 5 to 20 times the intended dose. The errors were linked to people new to self-injection, unfamiliar with withdrawing medication from a vial into a syringe, and confused between units of measurement. This is precisely why a generic article cannot teach vial-and-syringe measuring: that step must be set and demonstrated by your prescriber or pharmacist using your specific product’s IFU.

Feature	FDA-approved pen (Wegovy, Ozempic)	Compounded vial + syringe
FDA status	FDA-approved; reviewed for safety, effectiveness, quality	Not FDA-approved; not FDA-reviewed for safety, quality, or efficacy
Dose delivery	Built-in pen mechanism	User measures and withdraws from a vial
Documented risk	Standardized delivery	FDA: dosing errors up to 5 to 20x intended dose
Source of technique	Product IFU + pharmacist	Product IFU + pharmacist (mandatory)

Revive’s tirzepatide product is a compounded medication — compounded; not FDA-approved; not evaluated by the FDA for safety, quality, or efficacy. If you are comparing molecules, our tirzepatide vs. semaglutide overview explains the differences.

What does a general step-by-step look like?

The following is a general orientation only. Exact technique — priming, needle angle, how long to hold the pen against the skin — varies by device, so follow your pen’s IFU and the instruction your pharmacist gives you.

1. Wash your hands and gather supplies on a clean surface: your prescribed pen, an alcohol swab, and an FDA-cleared sharps container.
2. Inspect the medication as the IFU directs; do not use it if it looks discolored or has visible particles.
3. Choose and clean a site — abdomen, thigh, or upper arm — and rotate from the previous week’s spot.
4. Attach a new needle and prime exactly as your specific pen’s IFU instructs.
5. Inject and hold per the IFU, then dispose of the needle immediately in your sharps container.

Mild injection-site reactions and gastrointestinal effects such as nausea can occur, especially early on. Discuss anything that concerns you with your provider, and seek medical care for signs of a severe allergic reaction or a suspected overdose.

Why do prescribers start low and increase slowly?

You may have seen the dose “ladders” online. Presented here as label background only — not a schedule for you to follow on your own — these escalation steps exist mainly to improve gastrointestinal tolerability. A prescriber sets and adjusts every dose.

Product	Escalation per FDA label	Maximum
Wegovy (semaglutide)	0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg once weekly, increasing at ~4-week intervals (2.4 mg reached at week 17)	2.4 mg once weekly (maintenance; 1.7 mg is an allowed alternative for those who cannot tolerate 2.4 mg)
Ozempic (semaglutide)	0.25 mg for 4 weeks (initiation; “not effective for glycemic control”) → 0.5 → 1 → 2 mg once weekly	2 mg once weekly

The Wegovy ladder is drawn from the FDA Wegovy label; the Ozempic ladder, including the note that 0.25 mg “is not effective for glycemic control,” is from the Ozempic label. Note the maxima differ: Wegovy tops out at 2.4 mg, Ozempic at 2 mg — they are not interchangeable. For a fuller walkthrough of the schedule, see our semaglutide dosing chart.

What can I realistically expect from semaglutide?

Any number you encounter is a trial average in a specific population, not a promise. In STEP 1 (Wilding et al., NEJM 2021), once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% versus -2.4% with placebo over 68 weeks, in adults with overweight or obesity without diabetes. Crucially, both groups received lifestyle intervention — a reduced-calorie diet and increased physical activity. Individual results vary, and weight outcomes are provider-determined.

For context only: tirzepatide is a different drug, and figures from the SURMOUNT-1 trial (-15.0%, -19.5%, and -20.9% at 5, 10, and 15 mg over 72 weeks) belong to tirzepatide and must never be attributed to semaglutide. Timelines also vary; our overview of how long semaglutide takes to work covers what the evidence does and does not show.

How should I dispose of used needles?

The FDA recommends a two-step process. First, immediately place used needles and syringes in an FDA-cleared sharps disposal container — or, if one is not available, a sturdy, puncture-resistant household container. Second, dispose of the full container following your state and local guidelines, such as drop-off collection sites or mail-back programs. Never throw loose needles in the household trash, and never recap a needle unsafely.

Frequently asked questions

Where on the body do you inject semaglutide?

The FDA-approved labels permit subcutaneous injection in the abdomen, thigh, or upper arm. The site can be changed without a dosage modification, and the Ozempic label advises using a different site each week within the same body region. Follow your product’s IFU.

How often is semaglutide injected?

Once weekly, per the FDA-approved labels for Wegovy and Ozempic. The dosing day can be changed if necessary, as long as at least 2 days (>48 hours) separate two doses, according to the Ozempic label.

Is a pen safer than a vial and syringe?

FDA-approved pens have a built-in dosing mechanism and are reviewed by the FDA. The FDA has documented dosing errors of up to 5 to 20 times the intended dose with compounded vial-and-syringe products, often among people new to self-injection. Any vial measuring must be taught by your prescriber or pharmacist using the product IFU.

Can I set or change my own dose using the label ladders?

No. The escalation ladders in this article are label background that explains why prescribers start low and go slow for tolerability. Starting, changing, skipping, or self-managing a dose is for your prescriber to direct — not for you to do on your own.

Are compounded GLP-1s still freely available?

No. The FDA removed tirzepatide from the shortage list in October 2024 (declaratory order December 19, 2024), and the semaglutide shortage was declared resolved on February 21, 2025. Compounding wind-down ran to April 22, 2025 (503A) and May 22, 2025 (503B), after which large-scale compounding is no longer permitted.

How do I dispose of the needle after injecting?

Place it immediately in an FDA-cleared sharps container (or a sturdy, puncture-resistant container), never in loose household trash, then dispose of the full container per your state and local rules, per FDA sharps guidance.